In a report released yesterday, Frank Morgan from RBC Capital reiterated a Hold rating on DaVita (DVA), with a price target of $65. The company’s shares closed yesterday at $54.06.
According to TipRanks.com, Morgan is a top 100 analyst with an average return of 15.4% and a 64.9% success rate. Morgan covers the Services sector, focusing on stocks such as Tenet Healthcare, The Ensign Group, and Universal Health.
Currently, the analyst consensus on DaVita is a Moderate Buy with an average price target of $74, a 36.9% upside from current levels. In a report released yesterday, UBS also upgraded the stock to Hold with a $59 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $80.71 and a one-year low of $48.25. Currently, DaVita has an average volume of 1.86M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
DaVita, Inc. engages in the provision of medical care services. It operates through the following US Dialysis and Related Lab Services; and Other-Ancillary Services and Strategic Initiatives segments. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure.
